Clinical Trial Update: Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B [Phase 2]

View source ↗

Summary

This clinical trial update reports completion of a Phase 2, double-blind safety and immunogenicity study of Recombinant Botulinum Vaccine A/B for botulism. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Botulism

Drugs mentioned

• Recombinant Botulinum Vaccine A/B

Snippet

Sponsor: DynPort Vaccine Company LLC, A GDIT Company | Conditions: Botulism Vaccine | Phase 2 | Status: COMPLETED